Medical Devices; Exemption From Premarket Notification: Class II Devices; Surgical Apparel; Request for Comments, 56763-56765 [2017-25781]
Download as PDF
Federal Register / Vol. 82, No. 229 / Thursday, November 30, 2017 / Proposed Rules
56763
OTC or Rx
(date approved; date
Rx→OTC)
Route
(doses)
Indication
Labeled treatment duration
and schedule
Commit lozenge (nicotine
polacrilex) (NDA 021330;
GSK).
OTC (10/3/02; N/A) ...............
Oral (2, 4 mg) ...
Reduces withdrawal symptoms, including nicotine
craving, associated with
quitting smoking (under Directions: If you are under
18 years of age ask a doctor before use).
Nicorette mini lozenge (nicotine polacrilex) (NDA
022366; GSK).
OTC (5/18/09; N/A) ...............
Oral (2, 4 mg) ...
Same use as above ..............
12 weeks:
• Wk 1–6: 1 per 1–2 hr.
• Wk 7–9: 1 per 2–4 hr.
• Wk 10–12: 1 per 4–8
hr.
If smoke 1st cigarette within
30 min of waking up, use 4
mg; if more than 30 min,
use 2 mg.
12 weeks; same schedule as
Commit lozenge.
Product name
(NDA #; holder)
Dated: November 22, 2017.
Leslie Kux,
Associate Commissioner for Policy.
this proposed exemption, in accordance
with the Federal Food, Drug, and
Cosmetic Act (FD&C Act).
DATES: Submit either electronic or
written comments by January 29, 2018.
ADDRESSES: You may submit comments
as follows:
[FR Doc. 2017–25671 Filed 11–29–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 878
[Docket No. FDA–2017–N–4919]
Medical Devices; Exemption From
Premarket Notification: Class II
Devices; Surgical Apparel; Request for
Comments
AGENCY:
Food and Drug Administration,
HHS.
Proposed order; request for
comments.
ACTION:
The Food and Drug
Administration (FDA or Agency) is
announcing its intention to exempt
certain subtypes of surgical apparel
from premarket notification
requirements, subject to conditions and
limitations. FDA intends to limit the
proposed exemption to single-use,
disposable respiratory protective
devices (RPD) used in a healthcare
setting and worn by healthcare
personnel during procedures to protect
both the patient and the healthcare
personnel from the transfer of
microorganisms, body fluids, and
particulate material. These devices,
commonly referred to as N95 filtering
facepiece respirators (FFRs) and surgical
N95 respirators (herein collectively
referred to as N95s) are currently
regulated by FDA under product code
MSH. All other class II devices
classified under FDA’s surgical apparel
classification regulation would continue
to be subject to premarket notification
requirements. FDA is publishing this
document to obtain comments regarding
nshattuck on DSK9F9SC42PROD with PROPOSALS
SUMMARY:
VerDate Sep<11>2014
15:27 Nov 29, 2017
Jkt 244001
Electronic Submissions
Submit electronic comments in the
following way. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before January 29,
2018. The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of January 29, 2018.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
PO 00000
Frm 00015
Fmt 4702
Sfmt 4702
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–N–4919 for ‘‘Medical Devices;
Exemption From Premarket
Notification: Class II Devices; Surgical
Apparel; Request for Comments.’’
Received comments, those filed in a
timely manner (see ADDRESSES), will be
placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
E:\FR\FM\30NOP1.SGM
30NOP1
56764
Federal Register / Vol. 82, No. 229 / Thursday, November 30, 2017 / Proposed Rules
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Aftin Ross, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5402, Silver Spring,
MD 20993, 301–796–5679, email:
Aftin.Ross@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
nshattuck on DSK9F9SC42PROD with PROPOSALS
I. Statutory Background
Section 510(k) of the FD&C Act (21
U.S.C. 360(k)) and the implementing
regulations, 21 CFR part 807 subpart E,
require persons who intend to market a
new device to submit and obtain
clearance of a premarket notification
(510(k)) containing information that
allows FDA to determine whether the
new device is ‘‘substantially equivalent’’
within the meaning of section 513(i) of
the FD&C Act (21 U.S.C. 360c(i)) to a
legally marketed device that does not
require premarket approval.
The 21st Century Cures Act (Pub. L.
114–255) (Cures Act) was signed into
law on December 13, 2016. Section 3054
of the Cures Act amended section
510(m) of the FD&C Act. As amended,
section 510(m)(2) of the FD&C Act
provides that, 1 calendar day after the
date of publication of the final list under
paragraph (1)(B), FDA may exempt a
class II device from the requirement to
submit a report under section 510(k) of
the FD&C Act upon its own initiative or
a petition of an interested person, if
FDA determines that a report under
section 510(k) is not necessary to assure
the safety and effectiveness of the
device. To do so, FDA must publish in
the Federal Register notice of its intent
to exempt the device, or of the petition,
VerDate Sep<11>2014
15:27 Nov 29, 2017
Jkt 244001
and provide a 60-calendar day period
for public comment. Within 120 days
after the issuance of the notice, FDA
must publish an order in the Federal
Register that sets forth its final
determination regarding the exemption
of the device that was the subject of the
notice.
II. Factors FDA May Consider for
Exemption
There are a number of factors FDA
may consider to determine whether a
510(k) is necessary to provide
reasonable assurance of the safety and
effectiveness of a class II device. These
factors are discussed in the January 21,
1998, Federal Register notice (63 FR
3142) and subsequently in the guidance
the Agency issued on February 19, 1998,
entitled ‘‘Procedures for Class II Device
Exemptions From Premarket
Notification, Guidance for Industry and
CDRH Staff’’ (‘‘Class II 510(k)
Exemption Guidance’’) (Ref. 1).
Accordingly, FDA generally considers
the following factors to determine
whether a 510(k) is necessary for class
II devices: (1) The device does not have
a significant history of false or
misleading claims or of risks associated
with inherent characteristics of the
device; (2) characteristics of the device
necessary for its safe and effective
performance are well established; (3)
changes in the device that could affect
safety and effectiveness will either (a) be
readily detectable by users by visual
examination or other means such as
routine testing, before causing harm, or
(b) not materially increase the risk of
injury, incorrect diagnosis, or ineffective
treatment; and (4) any changes to the
device would not be likely to result in
a change in the device’s classification.
FDA may also consider that, even when
exempting devices, these devices would
still be subject to the limitations on
exemptions.
III. Proposed Class II Device Exemption
FDA, on its own initiative, is
proposing to exempt N95 filtering
facepiece respirators (FFRs) and surgical
N95 respirators (herein collectively
referred to as N95s) from 510(k), subject
to the conditions and limitations
described in this section. FDA considers
both of these devices to be a subset of
‘‘surgical apparel’’ intended to be worn
by healthcare personnel to protect both
the patient and the healthcare personnel
from transfer of microorganisms, body
fluids, and particulate material. As a
result, these devices fall under the
generic name ‘‘surgical apparel’’ and are
classified in 21 CFR 878.4040(b)(1). In
the Federal Register of June 24, 1988
(53 FR 23856), FDA issued a final rule
PO 00000
Frm 00016
Fmt 4702
Sfmt 4702
classifying surgical apparel into class II
(special controls). We are now
announcing our intent to exempt a
subset of surgical apparel devices
currently regulated under product code
MSH from 510(k) review. FDA has
assessed the need for 510(k) against the
criteria laid out in the Class II 510(k)
Exemption Guidance and determined
that these devices no longer require a
510(k) to provide reasonable assurance
of safety and effectiveness. However,
this exemption is limited and FDA’s
determination only applies to those
N95s under the conditions listed below.
FDA has a Memorandum of
Understanding (MOU) with the Centers
for Disease Control and Prevention
(CDC), acting through its National
Institute for Occupational Safety and
Health (NIOSH) regarding oversight of
N95s (Ref. 2). This agreement outlines
the structure through which both
Agencies will regulate N95s being
proposed for exemption from 510(k).
However, this MOU will not be effective
unless and until, FDA publishes an
order in the Federal Register, after
reviewing comments, that sets forth its
determination finalizing the 510(k)
exemption.
Although FDA and CDC share a
common public health mission, the
Agencies have different statutory
authorities and the distinct terminology
could lead to confusion among
stakeholders. In order to clearly identify
the devices that are subject to this
document, as well as the corresponding
MOU, the following definitions are
provided for the devices being proposed
for exemption.
The N95 FFR is a single-use
disposable, half-mask respiratory
protective device that covers the user’s
airway (nose and mouth) and offers
protection from particulate materials at
an N95 filtration efficiency level per 42
CFR 84.181. Such an N95 FFR used in
a healthcare setting is a class II device,
regulated by FDA under 21 CFR
878.4040.
The surgical N95 respirator is a
single-use, disposable respiratory
protective device used in a healthcare
setting that is worn by HCP during
procedures to protect both the patient
and HCP from the transfer of
microorganisms, body fluids, and
particulate material at an N95 filtration
efficiency level per 42 CFR 84.181. The
surgical N95 respirator is also a class II
device, regulated by FDA under 21 CFR
878.4040.
As described in the MOU, the
following conditions must be met for
N95s to be 510(k) exempt: (1)
Application submitted to NIOSH is
determined not to exceed the CDC and
E:\FR\FM\30NOP1.SGM
30NOP1
Federal Register / Vol. 82, No. 229 / Thursday, November 30, 2017 / Proposed Rules
FDA mutually agreed upon threshold
evaluation criteria and (2) such
applicants must have met approval
criteria and have NIOSH approval. N95s
with applications that meet the
mutually agreed upon threshold
evaluation criteria and approval criteria
and remain approved by NIOSH would
be exempt from FDA’s 510(k)
requirements under section 510(k) of the
FD&C Act. Unless an N95 meets the
mutually agreed upon threshold
evaluation criteria and approval criteria
and has NIOSH approval, the device
would still be subject to 510(k) review;
this includes devices with applications
pending NIOSH review, as well as
devices with no submitted applications.
N95s are the only devices included
within the scope of the MOU. As such,
this proposed exemption would only
apply to devices currently regulated by
FDA under product code MSH. If
finalized, this exemption would not
affect any other subset of surgical
apparel classified under 21 CFR
878.4040. In addition to being subject to
the general limitations to the
exemptions found in 21 CFR 878.9 and
the conditions of exemption identified
in this document, these devices will
also remain subject to current good
manufacturing practices and other
general controls under the statute. An
exemption from the requirement of
510(k) does not mean that the device is
exempt from any other statutory or
regulatory requirements, unless such
exemption is explicitly provided by
order or regulation.
nshattuck on DSK9F9SC42PROD with PROPOSALS
IV. References
The following references are on
display in the Dockets Management
Staff (see ADDRESSES) and are available
for viewing by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday; they are also available
electronically at https://
www.regulations.gov. FDA has verified
the Web site addresses, as of the date
this document publishes in the Federal
Register, but Web sites are subject to
change over time.
1. FDA Guidance, ‘‘Procedures for Class II
Device Exemptions from Premarket
Notification, Guidance for Industry and
CDRH Staff,’’ February 19, 1998,
available at https://www.fda.gov/
downloads/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/UCM080199.pdf.
2. ‘‘Memorandum of Understanding Between
the Food and Drug Administration,
Center for Devices and Radiological
Health, and the Centers for Disease
Control and Prevention, National
Institute for Occupational Safety and
Health, National Personal Protective
Technology Laboratory,’’ available at
VerDate Sep<11>2014
15:27 Nov 29, 2017
Jkt 244001
https://www.fda.gov/AboutFDA/
PartnershipsCollaborations/
MemorandaofUnderstandingMOUs/
DomesticMOUs/.
List of Subjects in 21 CFR Part 878
Medical devices.
Therefore, under the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 321
et seq., as amended) and under
authority delegated to the Commissioner
of Food and Drugs, it is proposed that
21 CFR part 878 be amended as follows:
PART 878—GENERAL AND PLASTIC
SURGERY DEVICES
1. The authority citation for part 878
continues to read as follows:
■
Authority: 21 U.S.C. 351, 360, 360c, 360e,
360j, 360l, 371.
2. In § 878.4040, revise paragraph
(b)(1) to read as follows:
■
§ 878.4040
Surgical apparel.
*
*
*
*
*
(b) * * *
(1) Class II (special controls) for
surgical gowns and surgical masks. A
surgical N95 respirator or N95 filtering
facepiece respirator is not exempt if it
is intended to prevent specific diseases
or infections, or it is labeled or
otherwise represented as filtering
surgical smoke or plumes, filtering
specific amounts of viruses or bacteria,
reducing the amount of and/or killing
viruses, bacteria, or fungi, or affecting
allergenicity, or it contains coating
technologies unrelated to filtration (e.g.,
to reduce and or kill microorganisms).
Surgical N95 respirators and N95
filtering facepiece respirators are
exempt from the premarket notification
procedures in subpart E of part 807 of
this chapter subject to § 878.9, and the
following conditions for exemption:
(i) The user contacting components of
the device must be demonstrated to be
biocompatible.
(ii) Analysis and nonclinical testing
must:
(A) Characterize flammability and be
demonstrated to be appropriate for the
intended environment of use; and
(B) Demonstrate the ability of the
device to resist penetration by fluids,
such as blood and body fluids, at a
velocity consistent with the intended
use of the device.
(iii) NIOSH approved under its
regulation.
*
*
*
*
*
Dated: November 24, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–25781 Filed 11–29–17; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00017
Fmt 4702
Sfmt 4702
56765
DEPARTMENT OF THE TREASURY
Internal Revenue Service
26 CFR Part 301
[REG–119337–17]
RIN 1545–BN95
Centralized Partnership Audit Regime:
International Tax Rules
Internal Revenue Service (IRS),
Treasury.
ACTION: Notice of proposed rulemaking.
AGENCY:
This document contains
proposed regulations implementing
section 1101 of the Bipartisan Budget
Act of 2015 (BBA), which was enacted
into law on November 2, 2015. Section
1101 of the BBA repeals the current
rules governing partnership audits and
replaces them with a new centralized
partnership audit regime that, in
general, assesses and collects tax at the
partnership level. These proposed
regulations provide rules addressing
how certain international rules operate
in the context of the centralized
partnership audit regime, including
rules relating to the withholding of tax
on foreign persons, withholding of tax
to enforce reporting on certain foreign
accounts, and the treatment of
creditable foreign tax expenditures of a
partnership.
DATES: Written or electronic comments
and requests for a public hearing must
be received by January 29, 2018.
ADDRESSES: Send submissions to:
CC:PA:LPD:PR (REG–119337–17), Room
5207, Internal Revenue Service, P.O.
Box 7604, Ben Franklin Station,
Washington, DC 20044. Submissions
may be hand delivered Monday through
Friday between the hours of 8:00 a.m.
and 4:00 p.m. to CC:PA:LPD:PR (REG–
119337–17), Courier’s Desk, Internal
Revenue Service, 1111 Constitution
Avenue NW., Washington, DC 20224, or
sent electronically via the Federal
eRulemaking Portal at
www.regulations.gov (IRS REG–119337–
17).
FOR FURTHER INFORMATION CONTACT:
Concerning the proposed regulations
relating to creditable foreign tax
expenditures, Larry R. Pounders, Jr., of
the Office of Associate Chief Counsel
(International), (202) 317–5465;
concerning the proposed regulations
relating to chapters 3 and 4 of subtitle
A of the Internal Revenue Code (other
than section 1446), Subin Seth of the
Office of Associate Chief Counsel
(International), (202) 317–5003;
concerning the proposed regulations
relating to section 1446, Ronald M.
SUMMARY:
E:\FR\FM\30NOP1.SGM
30NOP1
Agencies
[Federal Register Volume 82, Number 229 (Thursday, November 30, 2017)]
[Proposed Rules]
[Pages 56763-56765]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25781]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 878
[Docket No. FDA-2017-N-4919]
Medical Devices; Exemption From Premarket Notification: Class II
Devices; Surgical Apparel; Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Proposed order; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
its intention to exempt certain subtypes of surgical apparel from
premarket notification requirements, subject to conditions and
limitations. FDA intends to limit the proposed exemption to single-use,
disposable respiratory protective devices (RPD) used in a healthcare
setting and worn by healthcare personnel during procedures to protect
both the patient and the healthcare personnel from the transfer of
microorganisms, body fluids, and particulate material. These devices,
commonly referred to as N95 filtering facepiece respirators (FFRs) and
surgical N95 respirators (herein collectively referred to as N95s) are
currently regulated by FDA under product code MSH. All other class II
devices classified under FDA's surgical apparel classification
regulation would continue to be subject to premarket notification
requirements. FDA is publishing this document to obtain comments
regarding this proposed exemption, in accordance with the Federal Food,
Drug, and Cosmetic Act (FD&C Act).
DATES: Submit either electronic or written comments by January 29,
2018.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way. Please note that
late, untimely filed comments will not be considered. Electronic
comments must be submitted on or before January 29, 2018. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of January 29, 2018. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2017-N-4919 for ``Medical Devices; Exemption From Premarket
Notification: Class II Devices; Surgical Apparel; Request for
Comments.'' Received comments, those filed in a timely manner (see
ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and
[[Page 56764]]
contact information to be made publicly available, you can provide this
information on the cover sheet and not in the body of your comments and
you must identify this information as ``confidential.'' Any information
marked as ``confidential'' will not be disclosed except in accordance
with 21 CFR 10.20 and other applicable disclosure law. For more
information about FDA's posting of comments to public dockets, see 80
FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Aftin Ross, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5402, Silver Spring, MD 20993, 301-796-5679, email:
Aftin.Ross@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Statutory Background
Section 510(k) of the FD&C Act (21 U.S.C. 360(k)) and the
implementing regulations, 21 CFR part 807 subpart E, require persons
who intend to market a new device to submit and obtain clearance of a
premarket notification (510(k)) containing information that allows FDA
to determine whether the new device is ``substantially equivalent''
within the meaning of section 513(i) of the FD&C Act (21 U.S.C.
360c(i)) to a legally marketed device that does not require premarket
approval.
The 21st Century Cures Act (Pub. L. 114-255) (Cures Act) was signed
into law on December 13, 2016. Section 3054 of the Cures Act amended
section 510(m) of the FD&C Act. As amended, section 510(m)(2) of the
FD&C Act provides that, 1 calendar day after the date of publication of
the final list under paragraph (1)(B), FDA may exempt a class II device
from the requirement to submit a report under section 510(k) of the
FD&C Act upon its own initiative or a petition of an interested person,
if FDA determines that a report under section 510(k) is not necessary
to assure the safety and effectiveness of the device. To do so, FDA
must publish in the Federal Register notice of its intent to exempt the
device, or of the petition, and provide a 60-calendar day period for
public comment. Within 120 days after the issuance of the notice, FDA
must publish an order in the Federal Register that sets forth its final
determination regarding the exemption of the device that was the
subject of the notice.
II. Factors FDA May Consider for Exemption
There are a number of factors FDA may consider to determine whether
a 510(k) is necessary to provide reasonable assurance of the safety and
effectiveness of a class II device. These factors are discussed in the
January 21, 1998, Federal Register notice (63 FR 3142) and subsequently
in the guidance the Agency issued on February 19, 1998, entitled
``Procedures for Class II Device Exemptions From Premarket
Notification, Guidance for Industry and CDRH Staff'' (``Class II 510(k)
Exemption Guidance'') (Ref. 1). Accordingly, FDA generally considers
the following factors to determine whether a 510(k) is necessary for
class II devices: (1) The device does not have a significant history of
false or misleading claims or of risks associated with inherent
characteristics of the device; (2) characteristics of the device
necessary for its safe and effective performance are well established;
(3) changes in the device that could affect safety and effectiveness
will either (a) be readily detectable by users by visual examination or
other means such as routine testing, before causing harm, or (b) not
materially increase the risk of injury, incorrect diagnosis, or
ineffective treatment; and (4) any changes to the device would not be
likely to result in a change in the device's classification. FDA may
also consider that, even when exempting devices, these devices would
still be subject to the limitations on exemptions.
III. Proposed Class II Device Exemption
FDA, on its own initiative, is proposing to exempt N95 filtering
facepiece respirators (FFRs) and surgical N95 respirators (herein
collectively referred to as N95s) from 510(k), subject to the
conditions and limitations described in this section. FDA considers
both of these devices to be a subset of ``surgical apparel'' intended
to be worn by healthcare personnel to protect both the patient and the
healthcare personnel from transfer of microorganisms, body fluids, and
particulate material. As a result, these devices fall under the generic
name ``surgical apparel'' and are classified in 21 CFR 878.4040(b)(1).
In the Federal Register of June 24, 1988 (53 FR 23856), FDA issued a
final rule classifying surgical apparel into class II (special
controls). We are now announcing our intent to exempt a subset of
surgical apparel devices currently regulated under product code MSH
from 510(k) review. FDA has assessed the need for 510(k) against the
criteria laid out in the Class II 510(k) Exemption Guidance and
determined that these devices no longer require a 510(k) to provide
reasonable assurance of safety and effectiveness. However, this
exemption is limited and FDA's determination only applies to those N95s
under the conditions listed below.
FDA has a Memorandum of Understanding (MOU) with the Centers for
Disease Control and Prevention (CDC), acting through its National
Institute for Occupational Safety and Health (NIOSH) regarding
oversight of N95s (Ref. 2). This agreement outlines the structure
through which both Agencies will regulate N95s being proposed for
exemption from 510(k). However, this MOU will not be effective unless
and until, FDA publishes an order in the Federal Register, after
reviewing comments, that sets forth its determination finalizing the
510(k) exemption.
Although FDA and CDC share a common public health mission, the
Agencies have different statutory authorities and the distinct
terminology could lead to confusion among stakeholders. In order to
clearly identify the devices that are subject to this document, as well
as the corresponding MOU, the following definitions are provided for
the devices being proposed for exemption.
The N95 FFR is a single-use disposable, half-mask respiratory
protective device that covers the user's airway (nose and mouth) and
offers protection from particulate materials at an N95 filtration
efficiency level per 42 CFR 84.181. Such an N95 FFR used in a
healthcare setting is a class II device, regulated by FDA under 21 CFR
878.4040.
The surgical N95 respirator is a single-use, disposable respiratory
protective device used in a healthcare setting that is worn by HCP
during procedures to protect both the patient and HCP from the transfer
of microorganisms, body fluids, and particulate material at an N95
filtration efficiency level per 42 CFR 84.181. The surgical N95
respirator is also a class II device, regulated by FDA under 21 CFR
878.4040.
As described in the MOU, the following conditions must be met for
N95s to be 510(k) exempt: (1) Application submitted to NIOSH is
determined not to exceed the CDC and
[[Page 56765]]
FDA mutually agreed upon threshold evaluation criteria and (2) such
applicants must have met approval criteria and have NIOSH approval.
N95s with applications that meet the mutually agreed upon threshold
evaluation criteria and approval criteria and remain approved by NIOSH
would be exempt from FDA's 510(k) requirements under section 510(k) of
the FD&C Act. Unless an N95 meets the mutually agreed upon threshold
evaluation criteria and approval criteria and has NIOSH approval, the
device would still be subject to 510(k) review; this includes devices
with applications pending NIOSH review, as well as devices with no
submitted applications.
N95s are the only devices included within the scope of the MOU. As
such, this proposed exemption would only apply to devices currently
regulated by FDA under product code MSH. If finalized, this exemption
would not affect any other subset of surgical apparel classified under
21 CFR 878.4040. In addition to being subject to the general
limitations to the exemptions found in 21 CFR 878.9 and the conditions
of exemption identified in this document, these devices will also
remain subject to current good manufacturing practices and other
general controls under the statute. An exemption from the requirement
of 510(k) does not mean that the device is exempt from any other
statutory or regulatory requirements, unless such exemption is
explicitly provided by order or regulation.
IV. References
The following references are on display in the Dockets Management
Staff (see ADDRESSES) and are available for viewing by interested
persons between 9 a.m. and 4 p.m., Monday through Friday; they are also
available electronically at https://www.regulations.gov. FDA has
verified the Web site addresses, as of the date this document publishes
in the Federal Register, but Web sites are subject to change over time.
1. FDA Guidance, ``Procedures for Class II Device Exemptions from
Premarket Notification, Guidance for Industry and CDRH Staff,''
February 19, 1998, available at https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM080199.pdf.
2. ``Memorandum of Understanding Between the Food and Drug
Administration, Center for Devices and Radiological Health, and the
Centers for Disease Control and Prevention, National Institute for
Occupational Safety and Health, National Personal Protective
Technology Laboratory,'' available at https://www.fda.gov/AboutFDA/PartnershipsCollaborations/MemorandaofUnderstandingMOUs/DomesticMOUs/.
List of Subjects in 21 CFR Part 878
Medical devices.
Therefore, under the Federal Food, Drug, and Cosmetic Act (21
U.S.C. 321 et seq., as amended) and under authority delegated to the
Commissioner of Food and Drugs, it is proposed that 21 CFR part 878 be
amended as follows:
PART 878--GENERAL AND PLASTIC SURGERY DEVICES
0
1. The authority citation for part 878 continues to read as follows:
Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 360l, 371.
0
2. In Sec. 878.4040, revise paragraph (b)(1) to read as follows:
Sec. 878.4040 Surgical apparel.
* * * * *
(b) * * *
(1) Class II (special controls) for surgical gowns and surgical
masks. A surgical N95 respirator or N95 filtering facepiece respirator
is not exempt if it is intended to prevent specific diseases or
infections, or it is labeled or otherwise represented as filtering
surgical smoke or plumes, filtering specific amounts of viruses or
bacteria, reducing the amount of and/or killing viruses, bacteria, or
fungi, or affecting allergenicity, or it contains coating technologies
unrelated to filtration (e.g., to reduce and or kill microorganisms).
Surgical N95 respirators and N95 filtering facepiece respirators are
exempt from the premarket notification procedures in subpart E of part
807 of this chapter subject to Sec. 878.9, and the following
conditions for exemption:
(i) The user contacting components of the device must be
demonstrated to be biocompatible.
(ii) Analysis and nonclinical testing must:
(A) Characterize flammability and be demonstrated to be appropriate
for the intended environment of use; and
(B) Demonstrate the ability of the device to resist penetration by
fluids, such as blood and body fluids, at a velocity consistent with
the intended use of the device.
(iii) NIOSH approved under its regulation.
* * * * *
Dated: November 24, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-25781 Filed 11-29-17; 8:45 am]
BILLING CODE 4164-01-P